The recent results have clear and immediate clinical effects: anti–PD-1–PD-L1 therapy will become the foundation of the oncology panoply, possibly sparing patients toxic effects of chemotherapy, where deep investigation into tumor mutational load and immune interventions could usher a new wave of promising therapies. Here, CD274 is linked to neoplasm.